A májfunkció romlásának rizikófaktorai sikeres vesetranszplantációt követően = Risk factors for deterioration of liver functions after successful kidney transplantation
Abstract: Introduction: Increase of liver function is one of the most common complications after kidney transplantation due to the use of immunosuppressive therapy and hyperlipidemia in addition to hepatitis C virus (HCV) infection. Method: Following the selection criteria (n = 59), the study is bas...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2019
|
| Sorozat: | ORVOSI HETILAP
160 No. 5 |
| doi: | 10.1556/650.2019.31257 |
| mtmt: | 30413690 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/16076 |
| LEADER | 03119nab a2200301 i 4500 | ||
|---|---|---|---|
| 001 | publ16076 | ||
| 005 | 20220103153647.0 | ||
| 008 | 190711s2019 hu o 0|| magyar d | ||
| 022 | |a 0030-6002 | ||
| 024 | 7 | |a 10.1556/650.2019.31257 |2 doi | |
| 024 | 7 | |a 30413690 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a magyar | ||
| 100 | 1 | |a Borda Bernadett | |
| 245 | 1 | 2 | |a A májfunkció romlásának rizikófaktorai sikeres vesetranszplantációt követően = Risk factors for deterioration of liver functions after successful kidney transplantation |h [elektronikus dokumentum] / |c Borda Bernadett |
| 260 | |c 2019 | ||
| 300 | |a 186-190 | ||
| 490 | 0 | |a ORVOSI HETILAP |v 160 No. 5 | |
| 520 | 3 | |a Abstract: Introduction: Increase of liver function is one of the most common complications after kidney transplantation due to the use of immunosuppressive therapy and hyperlipidemia in addition to hepatitis C virus (HCV) infection. Method: Following the selection criteria (n = 59), the study is based on applied immunosuppressive therapy, baseline data of patients, further correlation between HCV and liver function deterioration. Patients were subjected to fasting laboratory examination to monitor serum electrolytes, uric acid and albumin levels. We looked at the effects of immunosuppressive therapy on the lipids (TG, TC, HDL, LDL) and liver enzymes (GOT, GPT, ALP, GGT). The analysis of the relationship between lipids and liver enzymes was also included in our study. Results: The data basics were not significantly different between the tacrolimus and the cyclosporine groups. In the laboratory results, Mg levels were significantly different between the two groups (p = 0.044). The impact of HCV on the liver function was significantly different on GGT (p = 0.008). We examed the lipids and liver function level between the tacrolimus and the patients receiving cyclosporine-based immunosuppression and the total cholesterol (p = 0.005) and GOT (p = 0.05) were significantly different between the two groups. Hyperlipidemia was associated with 26% of patients taking tacrolimus-based immunosuppression, and 89% of those receiving cyclosporine; the difference was significant (p = 0.002). Regarding the effect of hyperlipidemia on liver enzymes, ALP (p = 0.006) and GGT (p = 0.0001) were significantly higher. Conclusion: Increases in hepatic enzymes, ALT and GGT indicate the damage to hepatocytes. Beside the increase of liver function, which is the main risk factor in hepatitis on HCV soil, the applied immunosuppressive therapy and hyperlipidemia lead to degradation of allograft function and long-term graft loss. Orv hetil. 2019; 160(5): 186?190. | |
| 700 | 0 | 1 | |a Nemes Attila |e aut |
| 700 | 0 | 1 | |a Lengyel Csaba Attila |e aut |
| 700 | 0 | 1 | |a Várkonyi Tamás |e aut |
| 700 | 0 | 1 | |a Rárosi Ferenc |e aut |
| 700 | 0 | 1 | |a Keresztes Csilla |e aut |
| 700 | 0 | 1 | |a Ottlakán Aurél |e aut |
| 700 | 0 | 1 | |a Lázár György ifj. |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/16076/1/borda_majfunkcio_OH_2019-jan.pdf |z Dokumentum-elérés |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/16076/2/OH.jpg |z Dokumentum-elérés |